| | Children | Adult |
| Sex, % | | | Male | 44.4 | 42.1–58.3 [6–13] |
| Mean age (yr) | 9.2 | 40.1–56.6 [6–13] |
| Underlying disease, % | 58.4 | 33.3–76.9 [8, 11–14] |
| Causative factor, % | | | Drug-related | 72.3 | 52.4–100.0 [7–9, 11–13] | Non-drug-related | 27.7 | 0–47.6 [7–9, 11–13] |
| Prodromal symptoms, % | | | Fever | 69.4 | 59.8–94.7 [11, 13, 14] |
| Mucosal involvement, % | | | Oral | 97.2 | 38.6–85.4 [7, 8, 11, 13] | Eye | 83.3 | 59.8–64.4 [7, 8, 11, 13] | Genital | 72.2 | 32.9–41.4 [7, 8, 11, 13] | Anus | 16.7 | n/a | Nose | - | 3.6 [11] |
| Associated abnormalities, % | | | GI (Liver) abnormalities | 50.0 | 36.4–48.8 [7, 8, 11] | Renal abnormalities | 5.6 | 9.1–17.1 [7, 8, 11] | Lung abnormalities | - | 11.4 [8] | Encephalopathy | - | 8.0 [7, 8] |
| Treatment, % | | | Specific treatment | 77.8 | 46.6–97.7 [7–9, 11–13] | Supportive care only | 22.2 | 2.3–53.4 [7–9, 11–13] |
| Duration of hospital stay (d) | 11.8 | 10.0–37.0 [6–9, 11–14] |
| Short-term complication, % | | | Skin | | | Dyspigmentation | 72.2 | 13.7–69.0 [6, 12] | Nail change/loss | 11.1 | 2.9–46.0 [6, 7, 12] | Eye | 66.7 | 0–69.2 [7, 11, 12] | Conjunctivitis | 47.2 | n/a | Corneal epithelial defects | 16.7 | Unidentified [11] | Synechiae/symblepharon | 16.7 | Unidentified [11] | Pseudomembrane | 16.7 | 4.8 [11] | Superinfection | 27.8 | 8.0–56.2 [7, 8, 14] | Vaginal adhesion | 8.3 | 7.7 [12] | Pneumonia | 5.6 | 9.2 [7] | Pancreatitis | 2.8 | Cases report [15–17] | Adrenal insufficiency | 2.8 | Case report [18] |
| Long-term sequel, % | | | Skin | | | Dyspigmentation | 50.0 | 13.7–69.0 [6, 12] | Xerosis | 2.8 | n/a | Nail loss | 2.8 | 1.1 [7] | Eye | 36.1 | 9.8–77.0 [6, 11, 12, 19] | Dry eye | 27.8 | 31.0–32.4 [6, 12] | Corneal scar | 11.1 | 4.9–15.4 [6, 12] | Keratopathy | 8.3 | n/a | Subconjunctival fibrosis | 2.8 | n/a |
| Mortality rate, % | 0 | 6.8–34.4 [6–9, 11–14] |
|
|